Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder

Imagem de Miniatura
Arquivos
art_FORLENZA_Does_Lithium_Prevent_Alzheimer_s_Disease_2012.PDF (256 KB)
Citações na Scopus
45
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ADIS INT LTD
Autores
YATHAM, Lakshmi N.
Citação
CNS DRUGS, v.26, n.5, p.403-420, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Depot antipsychotics have been used as a strategy to reduce non-adherence to medications in schizophrenia and bipolar disorder (BD). This article reviews the literature on the efficacy and safety of first- and second-generation depot antipsychotics (FGDA and SGDA, respectively) for the maintenance treatment of BD. Although FGDA have been studied in BD, they have not been approved for use in this disease. Among the SGDA, only depot risperidone has been studied and approved for the maintenance treatment of BD. We found eight studies on FGDA (three on flupenthixol, two on depot haloperidol, one on fluphenazine and flupenthixol, two on a mix of diverse antipsychotics) and ten studies on SODA (all on depot risperidone). Differences in efficacy and safety were found between the two classes of depot antipsychotics. Although FGDA may be effective in reducing manic relapses, they possibly increase the risk of worsening depression. Depot risperidone is effective as a maintenance treatment in BD with effect noted predominantly for preventing mania. However, no worsening in depression was observed. Depot risperidone also is better tolerated than FGDA, mainly in relation to extrapyramidal symptoms. Studies with the new depot antipsychotics, olanzapine pamoate and paliperidone palmitate, are needed in BD patients. Further, there is currently little information on the metabolic changes (apart from bodyweight gain) that may occur with the use of depot risperidone in patients with bipolar disorder, and this issue needs further investigation.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/1110
Referências
  1. AHLFORS UG, 1981, ACTA PSYCHIAT SCAND, V64, P226, DOI 10.1111/j.1600-0447.1981.tb00778.x
  2. Angst Jules, 2005, Arch Suicide Res, V9, P279, DOI 10.1080/13811110590929488
  3. Bates JA, 2010, PRIM CARE COMPANION, V12
  4. Benabarre A, 2009, ACTAS ESP PSIQUIATRI, V37, P143
  5. Braunig P, 2008, INT J PSYCHIAT CLIN, V12, P74, DOI 10.1080/13651500701538161
  6. Brnabic AJM, 2011, INT J CLIN PRACT, V65, P945, DOI 10.1111/j.1742-1241.2011.02743.x
  7. Cavanagh J, 2004, ACTA PSYCHIAT SCAND, V109, P91, DOI 10.1046/j.1600-0447.2003.00274.x
  8. ESPARON J, 1986, BRIT J PSYCHIAT, V148, P723, DOI 10.1192/bjp.148.6.723
  9. Fu-I L, 2009, J CLIN PSYCHIAT, V70, P604
  10. Gonzalez-Pinto A, 2006, BIPOLAR DISORD, V8, P618, DOI 10.1111/j.1399-5618.2006.00368.x
  11. Gonzalez-Pinto A, 2010, Pharmacopsychiatry, V43, P263, DOI 10.1055/s-0030-1263169
  12. Haddad Peter M, 2009, Br J Psychiatry Suppl, V52, pS20, DOI 10.1192/bjp.195.52.s20
  13. Han C, 2007, PROG NEURO-PSYCHOPH, V31, P1219, DOI 10.1016/j.pnpbp.2007.04.017
  14. Hong JH, 2011, PSYCHIAT RES, V190, P110, DOI 10.1016/j.psychres.2011.04.016
  15. Kane John M, 2006, CNS Spectr, V11, P1
  16. Kauer-Sant'Anna M, 2009, COMPR PSYCHIAT, V50, P1, DOI 10.1016/j.comppsych.2008.05.013
  17. Leucht C, 2011, SCHIZOPHR RES, V127, P83, DOI 10.1016/j.schres.2010.11.020
  18. Lingam R, 2002, ACTA PSYCHIAT SCAND, V105, P164, DOI 10.1034/j.1600-0447.2002.1r084.x
  19. LITTLEJOHN R, 1994, BRIT J PSYCHIAT, V165, P827, DOI 10.1192/bjp.165.6.827
  20. Lopez-Jaramillo C, 2010, BIPOLAR DISORD, V12, P557, DOI 10.1111/j.1399-5618.2010.00835.x
  21. LOWE MR, 1985, BRIT J PSYCHIAT, V146, P558
  22. LOWE MR, 1986, INT CLIN PSYCHOPHARM, V1, P53
  23. Macfadden W, 2009, BIPOLAR DISORD, V11, P827, DOI 10.1111/j.1399-5618.2009.00761.x
  24. MacQueen GM, 2001, ACTA PSYCHIAT SCAND, V103, P163, DOI 10.1034/j.1600-0447.2001.00059.x
  25. Malempati RN, 2008, INT CLIN PSYCHOPHARM, V23, P88, DOI 10.1097/YIC.0b013e3282f2b4c5
  26. McEvoy JP, 2006, J CLIN PSYCHIAT, V67, P15
  27. Merikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P543, DOI 10.1001/archpsyc.64.5.543
  28. Miklowitz DJ, 2011, CURR PSYCHIAT REP, V13, P504, DOI 10.1007/s11920-011-0227-x
  29. MULLEROERLINGHAUSEN B, 1992, J AFFECT DISORDERS, V25, P261, DOI 10.1016/0165-0327(92)90084-J
  30. NAYLOR GJ, 1980, BRIT J PSYCHIAT, V136, P105
  31. Perlis RH, 2010, J CLIN PSYCHIAT, V71, P296, DOI 10.4088/JCP.09m05514yel
  32. Quiroz JA, 2010, BIOL PSYCHIAT, V68, P156, DOI 10.1016/j.biopsych.2010.01.015
  33. Rosa AR, 2010, VALUE HEALTH, V13, P984, DOI 10.1111/j.1524-4733.2010.00768.x
  34. Rosa AR, 2009, BIPOLAR DISORD, V11, P401, DOI 10.1111/j.1399-5618.2009.00698.x
  35. Savas HA, 2006, J CLIN PSYCHOPHARM, V26, P530, DOI 10.1097/01.jcp.0000231609.91144.00
  36. Scott J, 2002, AM J PSYCHIAT, V159, P1927, DOI 10.1176/appi.ajp.159.11.1927
  37. SUPPES T, 1991, ARCH GEN PSYCHIAT, V48, P1082
  38. Taylor David, 2009, Br J Psychiatry Suppl, V52, pS13, DOI 10.1192/bjp.195.52.s13
  39. Tohen M, 2000, AM J PSYCHIAT, V157, P220, DOI 10.1176/appi.ajp.157.2.220
  40. Torres I.J., 2007, ACTA PSYCHIAT SCAND, V434, P17
  41. Vieta E, 2008, WORLD J BIOL PSYCHIA, V9, P219, DOI 10.1080/15622970701530917
  42. WHITE E, 1993, INT CLIN PSYCHOPHARM, V8, P119, DOI 10.1097/00004850-199300820-00007
  43. Yatham L N, 2007, Acta Psychiatr Scand Suppl, P50

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21